These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 19052918

  • 1. Short or long survival in multiple myeloma. A simple method for determining the prognosis.
    Várkonyi J, Bajzik E, Fazakas A, Sipka S, Karádi I.
    Pathol Oncol Res; 2009 Sep; 15(3):383-7. PubMed ID: 19052918
    [Abstract] [Full Text] [Related]

  • 2. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
    Mihou D, Katodritou E, Zervas K.
    Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma.
    Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR.
    Semin Hematol; 2009 Apr; 46(2):110-7. PubMed ID: 19389494
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients.
    Rapoport BL, Falkson HC, Falkson G.
    S Afr Med J; 1991 Jan 19; 79(2):65-7. PubMed ID: 1989088
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The Merlini, Waldenström, Jayakar staging system revisited.
    Merlini G, Gobbi PG, Ascari E.
    Eur J Haematol Suppl; 1989 Jan 19; 51():105-10. PubMed ID: 2697581
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Clinical features and survival of Chilean patients with multiple myeloma].
    Conté L G, Figueroa M G, Lois V V, Cabrera C ME, León R A, García L H, Rojas R H.
    Rev Med Chil; 2007 Sep 19; 135(9):1111-7. PubMed ID: 18064364
    [Abstract] [Full Text] [Related]

  • 12. The Effect of Suppressed Levels of Uninvolved Immunoglobulins on the Prognosis of Symptomatic Multiple Myeloma.
    Sarı M, Sarı S, Nalçacı M.
    Turk J Haematol; 2017 Jun 05; 34(2):131-136. PubMed ID: 27795224
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of a morphologic staging method (myeloma progression score) in multiple myeloma].
    Pasqualetti P, Casale R, Collacciani A, Colantonio D.
    Medicina (Firenze); 1989 Jun 05; 9(3):280-2. PubMed ID: 2615598
    [Abstract] [Full Text] [Related]

  • 14. [Prognostic significance of skeletal lesions in multiple myeloma].
    Bettini R, Anzani P, Quadrelli CM, Mammano S, Rapazzini P, Marrapodi E, Sessa V.
    Recenti Prog Med; 1989 Jun 05; 80(6):300-3. PubMed ID: 2672192
    [Abstract] [Full Text] [Related]

  • 15. International Staging System required standardization of biochemical laboratory testing in multiple myeloma.
    Tichý M, Maisnar V, Palicka V, Friedecký B, Vávrová J, Novotná H, Cermáková Z, Dastych M, Cechák P, Vogtová D, Jarolímková E, Benáková H, Hachová L, Bezdícková D, Kouril F, Zábranská EA, Zenková J, Slabý P, Scudla V, Gregora E, Spicka I, Straub J, Schützova M, Hájek R.
    Neoplasma; 2006 Jun 05; 53(6):492-4. PubMed ID: 17167717
    [Abstract] [Full Text] [Related]

  • 16. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience.
    Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ, Southwest Oncology Group.
    Br J Haematol; 2003 Aug 05; 122(3):441-50. PubMed ID: 12877671
    [Abstract] [Full Text] [Related]

  • 17. [Prognostic factors in IgG and micromolecular multiple myeloma. Retrospective analysis of 50 consecutive cases].
    Pasqualetti P, Casale R, Colantonio D, Festuccia V, Di Lauro G, Natali G.
    Minerva Med; 1987 May 15; 78(9):603-8. PubMed ID: 3587727
    [Abstract] [Full Text] [Related]

  • 18. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
    Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Duguet C, Duhamel A, Facon T.
    Hematol J; 2002 May 15; 3(4):185-92. PubMed ID: 12189564
    [Abstract] [Full Text] [Related]

  • 19. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma.
    Kim JE, Yoo C, Lee DH, Kim SW, Lee JS, Suh C.
    Ann Hematol; 2010 Apr 15; 89(4):391-7. PubMed ID: 19844712
    [Abstract] [Full Text] [Related]

  • 20. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM.
    Cancer; 2003 May 15; 97(10):2440-52. PubMed ID: 12733143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.